Evaluation of HER-2/neu expression in prostatic adenocarcinoma

A request for a standardized, organ specific methodology

Katya M. Sanchez, Christopher J. Sweeney, Robert Mass, Michael Koch, George J. Eckert, William A. Geary, Lee Ann Baldridge, Shaobo Zhang, John Eble, Liang Cheng

Research output: Contribution to journalArticle

40 Citations (Scopus)

Abstract

BACKGROUND. Some evidence suggests a role for HER-2/neu overexpression in prostate carcinoma progression. Reported rates of HER-2/neu overexpression in patients with prostate carcinoma vary greatly. METHODS. The authors studied radical prostatectomy specimens from 38 patients who had biochemical failure after undergoing radical prostatectomy for prostate carcinoma. Immunohistochemistry for HER-2/neu overexpression using the HercepTest kit (Dako Corporation, Carpenteria, CA) was employed. Two different antigen-retrieval techniques were used: 1) the standard U.S. Food and Drug Administration (FDA)-approved HercepTest assay and 2) a modified HercepTest, which employed an alkaline citrate buffer, pH 9.0, for antigen retrieval and a 1-hour primary antibody incubation time. The level of HER-2/neu expression was evaluated on a scale from 0 (no staining) to 3+ according to the published guidelines. Fluorescent in situ hybridization for gene amplification was performed on all specimens. RESULTS. With the standard technique, only one specimen had 2+ staining, and no specimens had 3+ staining. With the modified technique, 10 specimens (26%) had 2+ staining, and 9 specimens (24%) had 3+ staining. There was a significant association between the level of HER-2/neu expression shown with the modified technique and tumor stage (P = 0.03) as well as Gleason grade (P = 0.01). None of the specimens had HER-2/neu gene amplification. CONCLUSIONS. The authors report a simple modification of the HercepTest that resulted in an increased rate of HER-2/neu expression, which was correlated with poor-risk pathologic findings. The findings suggest that adenocarcinoma of the prostate should be evaluated for HER-2/neu expression with a prostate specific immunohistochemical procedure that differs from the FDA-approved standard procedure.

Original languageEnglish
Pages (from-to)1650-1655
Number of pages6
JournalCancer
Volume95
Issue number8
DOIs
StatePublished - Oct 15 2002

Fingerprint

Prostate
Adenocarcinoma
Staining and Labeling
erbB-2 Genes
Gene Amplification
United States Food and Drug Administration
Prostatectomy
Carcinoma
Antigens
Fluorescence In Situ Hybridization
Citric Acid
Buffers
Immunohistochemistry
Guidelines
Antibodies
Neoplasms

Keywords

  • Antigen retrieval
  • Biomarkers
  • HER-2/neu
  • HercepTest™
  • Prognosis
  • Prostatic neoplasms
  • Radical prostatectomy

ASJC Scopus subject areas

  • Cancer Research
  • Oncology

Cite this

Evaluation of HER-2/neu expression in prostatic adenocarcinoma : A request for a standardized, organ specific methodology. / Sanchez, Katya M.; Sweeney, Christopher J.; Mass, Robert; Koch, Michael; Eckert, George J.; Geary, William A.; Baldridge, Lee Ann; Zhang, Shaobo; Eble, John; Cheng, Liang.

In: Cancer, Vol. 95, No. 8, 15.10.2002, p. 1650-1655.

Research output: Contribution to journalArticle

Sanchez, Katya M. ; Sweeney, Christopher J. ; Mass, Robert ; Koch, Michael ; Eckert, George J. ; Geary, William A. ; Baldridge, Lee Ann ; Zhang, Shaobo ; Eble, John ; Cheng, Liang. / Evaluation of HER-2/neu expression in prostatic adenocarcinoma : A request for a standardized, organ specific methodology. In: Cancer. 2002 ; Vol. 95, No. 8. pp. 1650-1655.
@article{f4d270658e914c24bcc4b6f8e16af2a5,
title = "Evaluation of HER-2/neu expression in prostatic adenocarcinoma: A request for a standardized, organ specific methodology",
abstract = "BACKGROUND. Some evidence suggests a role for HER-2/neu overexpression in prostate carcinoma progression. Reported rates of HER-2/neu overexpression in patients with prostate carcinoma vary greatly. METHODS. The authors studied radical prostatectomy specimens from 38 patients who had biochemical failure after undergoing radical prostatectomy for prostate carcinoma. Immunohistochemistry for HER-2/neu overexpression using the HercepTest kit (Dako Corporation, Carpenteria, CA) was employed. Two different antigen-retrieval techniques were used: 1) the standard U.S. Food and Drug Administration (FDA)-approved HercepTest assay and 2) a modified HercepTest, which employed an alkaline citrate buffer, pH 9.0, for antigen retrieval and a 1-hour primary antibody incubation time. The level of HER-2/neu expression was evaluated on a scale from 0 (no staining) to 3+ according to the published guidelines. Fluorescent in situ hybridization for gene amplification was performed on all specimens. RESULTS. With the standard technique, only one specimen had 2+ staining, and no specimens had 3+ staining. With the modified technique, 10 specimens (26{\%}) had 2+ staining, and 9 specimens (24{\%}) had 3+ staining. There was a significant association between the level of HER-2/neu expression shown with the modified technique and tumor stage (P = 0.03) as well as Gleason grade (P = 0.01). None of the specimens had HER-2/neu gene amplification. CONCLUSIONS. The authors report a simple modification of the HercepTest that resulted in an increased rate of HER-2/neu expression, which was correlated with poor-risk pathologic findings. The findings suggest that adenocarcinoma of the prostate should be evaluated for HER-2/neu expression with a prostate specific immunohistochemical procedure that differs from the FDA-approved standard procedure.",
keywords = "Antigen retrieval, Biomarkers, HER-2/neu, HercepTest™, Prognosis, Prostatic neoplasms, Radical prostatectomy",
author = "Sanchez, {Katya M.} and Sweeney, {Christopher J.} and Robert Mass and Michael Koch and Eckert, {George J.} and Geary, {William A.} and Baldridge, {Lee Ann} and Shaobo Zhang and John Eble and Liang Cheng",
year = "2002",
month = "10",
day = "15",
doi = "10.1002/cncr.10839",
language = "English",
volume = "95",
pages = "1650--1655",
journal = "Cancer",
issn = "0008-543X",
publisher = "John Wiley and Sons Inc.",
number = "8",

}

TY - JOUR

T1 - Evaluation of HER-2/neu expression in prostatic adenocarcinoma

T2 - A request for a standardized, organ specific methodology

AU - Sanchez, Katya M.

AU - Sweeney, Christopher J.

AU - Mass, Robert

AU - Koch, Michael

AU - Eckert, George J.

AU - Geary, William A.

AU - Baldridge, Lee Ann

AU - Zhang, Shaobo

AU - Eble, John

AU - Cheng, Liang

PY - 2002/10/15

Y1 - 2002/10/15

N2 - BACKGROUND. Some evidence suggests a role for HER-2/neu overexpression in prostate carcinoma progression. Reported rates of HER-2/neu overexpression in patients with prostate carcinoma vary greatly. METHODS. The authors studied radical prostatectomy specimens from 38 patients who had biochemical failure after undergoing radical prostatectomy for prostate carcinoma. Immunohistochemistry for HER-2/neu overexpression using the HercepTest kit (Dako Corporation, Carpenteria, CA) was employed. Two different antigen-retrieval techniques were used: 1) the standard U.S. Food and Drug Administration (FDA)-approved HercepTest assay and 2) a modified HercepTest, which employed an alkaline citrate buffer, pH 9.0, for antigen retrieval and a 1-hour primary antibody incubation time. The level of HER-2/neu expression was evaluated on a scale from 0 (no staining) to 3+ according to the published guidelines. Fluorescent in situ hybridization for gene amplification was performed on all specimens. RESULTS. With the standard technique, only one specimen had 2+ staining, and no specimens had 3+ staining. With the modified technique, 10 specimens (26%) had 2+ staining, and 9 specimens (24%) had 3+ staining. There was a significant association between the level of HER-2/neu expression shown with the modified technique and tumor stage (P = 0.03) as well as Gleason grade (P = 0.01). None of the specimens had HER-2/neu gene amplification. CONCLUSIONS. The authors report a simple modification of the HercepTest that resulted in an increased rate of HER-2/neu expression, which was correlated with poor-risk pathologic findings. The findings suggest that adenocarcinoma of the prostate should be evaluated for HER-2/neu expression with a prostate specific immunohistochemical procedure that differs from the FDA-approved standard procedure.

AB - BACKGROUND. Some evidence suggests a role for HER-2/neu overexpression in prostate carcinoma progression. Reported rates of HER-2/neu overexpression in patients with prostate carcinoma vary greatly. METHODS. The authors studied radical prostatectomy specimens from 38 patients who had biochemical failure after undergoing radical prostatectomy for prostate carcinoma. Immunohistochemistry for HER-2/neu overexpression using the HercepTest kit (Dako Corporation, Carpenteria, CA) was employed. Two different antigen-retrieval techniques were used: 1) the standard U.S. Food and Drug Administration (FDA)-approved HercepTest assay and 2) a modified HercepTest, which employed an alkaline citrate buffer, pH 9.0, for antigen retrieval and a 1-hour primary antibody incubation time. The level of HER-2/neu expression was evaluated on a scale from 0 (no staining) to 3+ according to the published guidelines. Fluorescent in situ hybridization for gene amplification was performed on all specimens. RESULTS. With the standard technique, only one specimen had 2+ staining, and no specimens had 3+ staining. With the modified technique, 10 specimens (26%) had 2+ staining, and 9 specimens (24%) had 3+ staining. There was a significant association between the level of HER-2/neu expression shown with the modified technique and tumor stage (P = 0.03) as well as Gleason grade (P = 0.01). None of the specimens had HER-2/neu gene amplification. CONCLUSIONS. The authors report a simple modification of the HercepTest that resulted in an increased rate of HER-2/neu expression, which was correlated with poor-risk pathologic findings. The findings suggest that adenocarcinoma of the prostate should be evaluated for HER-2/neu expression with a prostate specific immunohistochemical procedure that differs from the FDA-approved standard procedure.

KW - Antigen retrieval

KW - Biomarkers

KW - HER-2/neu

KW - HercepTest™

KW - Prognosis

KW - Prostatic neoplasms

KW - Radical prostatectomy

UR - http://www.scopus.com/inward/record.url?scp=0037108288&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0037108288&partnerID=8YFLogxK

U2 - 10.1002/cncr.10839

DO - 10.1002/cncr.10839

M3 - Article

VL - 95

SP - 1650

EP - 1655

JO - Cancer

JF - Cancer

SN - 0008-543X

IS - 8

ER -